Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: DewDiligence_on_SI who wrote (51922)	1/31/2022 10:46:38 PM
From: A.J. Mullen	Read Replies (2) \| Respond to of 52153

Thanks. I had read that, but didn't dwell on the distinction between a presumed and confirmed condition. My assumption was that if the drug worked on those suffering from NASH, then diluting the patient population would make it tougher to detect significance. On further thought - a candidate drug is as likely to be more effective against the symptoms, and that would bias the trial in favor of the drug. Ashley